Insmed management is waiting for the trial to be over and not releasing any PR because the trial "overhang" would dilute the effect. Once the trial is over and assuming Insmed wins, management will roll out a planned PR campaign to coincide with key events in an attempt to increase share price, let's say around $3. Then when they have to raise cash in 2007 Q2 the number of shares offered is much more palatable and less dilutive to share holders.
IMO Insmed will do everything to go it alone unless a partner approaches them with a "sweet heart" deal that they can't refuse and lets them pursue their scientific and medical mission.
News 
Market Data 
Discover 
